ArticleInflammation2026
Propofol Inhibits Neutrophil Extracellular Traps Formation and Alleviates Sepsis-Induced Acute Lung Injury.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundExcessive neutrophil extracellular traps (NETs) formation contributes to lung tissue injury in sepsis-associated acute lung injury (ALI). Propofol, a commonly used sedative with anti-inflammatory and antioxidant properties, has been suggested to confer protection against ALI; however, its effects on NET sformation and the underlying mechanisms remain poorly defined. METHODS AND
resultsAt the cellular level, we established an in vitro model of lipopolysaccharide (LPS)-induced NET formation using human peripheral blood neutrophils to evaluate the effects of propofol. Pharmacological inhibition experiments in vitro suggested that propofol may suppress NET release by modulating Akt/mTOR signaling, with a concomitant reduction in neutrophil autophagic activity. In parallel, we established an LPS-induced sepsis model in mice and administered propofol by intraperitoneal pretreatment. Lung histopathology and NET quantification showed that propofol treatment was associated with attenuated sepsis‑induced lung injury and suppressed NET formation in vivo. These protective effects were associated with increased Akt/mTOR pathway activity in lung tissue; however, because in vivo pathway blockade was not performed, the functional contribution of Akt/mTOR signaling to organ protection in this setting remains to be directly validated.
conclusionsPropofol attenuates sepsis-induced lung injury in association with suppressed NET formation. In vitro pharmacological inhibition experiments suggest that the Akt/mTOR axis may represent one pathway through which propofol suppresses NET release. However, direct in vivo validation of this mechanism (e.g., using pathway-specific inhibitors, conditional knockout models, or other loss-of-function approaches) remains necessary and should be addressed in future studies. Collectively, these findings identify a previously underappreciated mechanism of propofol action and support its potential adjunctive role in sepsis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.